Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
TELK's Cash to Debt is ranked higher than
98% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. TELK: No Debt )
TELK' s 10-Year Cash to Debt Range
Min: 6.57   Max: No Debt
Current: No Debt

Interest Coverage No Debt
TELK's Interest Coverage is ranked higher than
88% of the 460 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 88.77 vs. TELK: No Debt )
TELK' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 1
Z-Score: -296.41
M-Score: -2.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -316.01
TELK's ROE (%) is ranked lower than
60% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. TELK: -316.01 )
TELK' s 10-Year ROE (%) Range
Min: -316.01   Max: -26.06
Current: -316.01

-316.01
-26.06
ROA (%) -200.38
TELK's ROA (%) is ranked lower than
60% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. TELK: -200.38 )
TELK' s 10-Year ROA (%) Range
Min: -200.38   Max: -24.31
Current: -200.38

-200.38
-24.31
EBITDA Growth (%) -56.70
TELK's EBITDA Growth (%) is ranked lower than
58% of the 507 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. TELK: -56.70 )
TELK' s 10-Year EBITDA Growth (%) Range
Min: -56.7   Max: 37
Current: -56.7

-56.7
37
EPS Growth (%) -56.10
TELK's EPS Growth (%) is ranked lower than
57% of the 510 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. TELK: -56.10 )
TELK' s 10-Year EPS Growth (%) Range
Min: -56.1   Max: 35.4
Current: -56.1

-56.1
35.4
» TELK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

TELK Guru Trades in Q4 2012

Jim Simons 75,852 sh (-3.8%)
» More
Q1 2013

TELK Guru Trades in Q1 2013

Jim Simons 38,852 sh (-48.78%)
» More
Q2 2013

TELK Guru Trades in Q2 2013

Jim Simons 18,252 sh (-53.02%)
» More
Q3 2013

TELK Guru Trades in Q3 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with TELK



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.80
TELK's P/B is ranked higher than
55% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. TELK: 3.80 )
TELK' s 10-Year P/B Range
Min: 0.01   Max: 12.43
Current: 3.8

0.01
12.43
EV-to-EBIT 76.90
TELK's EV-to-EBIT is ranked lower than
67% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.45 vs. TELK: 76.90 )
TELK' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 76.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.89
TELK's Price/Net Cash is ranked higher than
82% of the 214 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.10 vs. TELK: 4.89 )
TELK' s 10-Year Price/Net Cash Range
Min: 0.51   Max: 7.97
Current: 4.89

0.51
7.97
Price/Net Current Asset Value 4.89
TELK's Price/Net Current Asset Value is ranked higher than
75% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.80 vs. TELK: 4.89 )
TELK' s 10-Year Price/Net Current Asset Value Range
Min: 0.51   Max: 7.97
Current: 4.89

0.51
7.97
Price/Tangible Book 3.81
TELK's Price/Tangible Book is ranked higher than
56% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. TELK: 3.81 )
TELK' s 10-Year Price/Tangible Book Range
Min: 0.33   Max: 7.34
Current: 3.81

0.33
7.34
Forward Rate of Return (Yacktman) -605.26
TELK's Forward Rate of Return (Yacktman) is ranked lower than
58% of the 532 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. TELK: -605.26 )
TELK' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -605.26

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:TK8N.Germany
Telik, Inc., was incorporated in Delaware in 1988. The Company is engaged in the discovery, development and commercialization of novel small molecule drugs to treat cancer and other serious diseases. Its drug product candidate in clinical development, TELINTRA, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1, which is under Phase II clinical trial for the treatment of blood disorders associated with low blood cell levels, such as neutropenia or anemia. The company is also developing TELCYTA, a cancer cell-activated chemotherapeutic, which has been in multiple Phase II and Phase III trials in patients with advanced ovarian cancer, non-small cell lung cancer, colon cancer, and breast cancer. Its preclinical drug product developments include TLK60404, a small molecule compound, which inhibits both Aurora kinase and VEGFR kinase; TLK60357, a novel, small molecule inhibitor of cell division; and TLK60596, a VGFR kinase inhibitor that blocks the formation of new blood vessels in tumors. The Company's product candidates are discovered using its proprietary technology, target-related affinity profiling, which enables the discovery of small molecule product candidates.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide